Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06460844 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
A Phase 1 study of Retinitis Pigmentosa and Choroideremia, sponsored by Ray Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT06460844: Active Phase 1 study of Retinitis Pigmentosa and Choroideremia, sponsored by Ray Therapeutics.
NCT06460844 is a Phase 1 study of Retinitis Pigmentosa and Choroideremia that is active but no longer recruiting, run by Ray Therapeutics. The registered enrollment target is 10 participants, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06460844, a Phase 1 study of Retinitis Pigmentosa and Choroideremia, is active but no longer recruiting, sponsored by Ray Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 5 years.
Primary Outcome
The number of patients in each cohort with treatment-emergent adverse events categorized using MedDRA v24.0 or higher
Conditions Studied
Interventions
- GENETIC RTx-015
Study Locations (4)
California
- Retina Vitreous Associates Medical Group - Beverly Hills
- UCI Alpha Clinic - Orange
Pennsylvania
- UPMC Vision Institute - Pittsburgh
Texas
- Retina Consultants of Texas Research Centers - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-08-27 |
| Est. Completion | 2030-10 |
| Phase | Phase 1 |
What the registry record for NCT06460844 still lists
NCT06460844 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 261-participant average among 37 other Retinitis Pigmentosa trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which RTx-015 is the first listed.
NCT06460844 reports a single indexed study location in California, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT06460844 about?
NCT06460844 is a clinical study titled "Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)". A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in...
What is the current status of trial NCT06460844?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-08-27. Estimated completion is 2030-10.
What conditions does trial NCT06460844 study?
This clinical trial studies the following conditions: Retinitis Pigmentosa, Choroideremia.
What interventions are being tested in trial NCT06460844?
The interventions under investigation include: RTx-015 (GENETIC).
Who is sponsoring clinical trial NCT06460844?
This trial is sponsored by Ray Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06460844 being conducted?
This trial has 4 study locations across California, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06460844's enrollment target sits among peer trials
10 35th of 37 higher than 3 of 37 other Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Promising ROd-cone DYstrophy Gene therapY
RECRUITING · Phase 1
-
A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
RECRUITING · Phase 1
-
BS01 in Patients With Retinitis Pigmentosa
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
ACTIVE NOT RECRUITING · Phase 1
-
CNS10-NPC for the Treatment of RP
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI